18083690

Source:http://linkedlifedata.com/resource/pubmed/id/18083690

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013216, umls-concept:C0024299, umls-concept:C0038952, umls-concept:C0055598, umls-concept:C0332161, umls-concept:C0393022, umls-concept:C0439682, umls-concept:C0450094, umls-concept:C0687697, umls-concept:C1413947, umls-concept:C1519275, umls-concept:C1883548, umls-concept:C1883712, umls-concept:C2919019
pubmed:issue	3
pubmed:dateCreated	2008-2-28
pubmed:abstractText	The benefit of adding rituximab to anthracycline-based therapy for follicular lymphoma grade 3 has not been studied.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal..., http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Prednisone, http://linkedlifedata.com/resource/pubmed/chemical/Vincristine, http://linkedlifedata.com/resource/pubmed/chemical/rituximab
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	1569-8041
pubmed:author	pubmed-author:CabanillasFF, pubmed-author:FayadL ELE, pubmed-author:FengLL, pubmed-author:HagemeisterF BFB, pubmed-author:HessMM, pubmed-author:KwanCC, pubmed-author:McLaughlinPP, pubmed-author:OvermanM JMJ, pubmed-author:ProBB, pubmed-author:RodriguezM AMA, pubmed-author:RomagueraJ EJE, pubmed-author:SamaniegoFF, pubmed-author:YounesAA
pubmed:issnType	Electronic
pubmed:volume	19
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	553-9
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:18083690-Adult, pubmed-meshheading:18083690-Aged, pubmed-meshheading:18083690-Aged, 80 and over, pubmed-meshheading:18083690-Antibodies, Monoclonal, pubmed-meshheading:18083690-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:18083690-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18083690-Cohort Studies, pubmed-meshheading:18083690-Cyclophosphamide, pubmed-meshheading:18083690-Disease-Free Survival, pubmed-meshheading:18083690-Doxorubicin, pubmed-meshheading:18083690-Female, pubmed-meshheading:18083690-Follow-Up Studies, pubmed-meshheading:18083690-Humans, pubmed-meshheading:18083690-Lymphoma, Follicular, pubmed-meshheading:18083690-Male, pubmed-meshheading:18083690-Middle Aged, pubmed-meshheading:18083690-Prednisone, pubmed-meshheading:18083690-Proportional Hazards Models, pubmed-meshheading:18083690-Salvage Therapy, pubmed-meshheading:18083690-Survival Rate, pubmed-meshheading:18083690-Vincristine
pubmed:year	2008
pubmed:articleTitle	The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.
pubmed:affiliation	Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
pubmed:publicationType	Journal Article